OncoSil Launches $8M Equity Raise Amid Growing European Market Adoption

OncoSil Medical’s Strategic Capital Raise

OncoSil Medical Ltd (ASX – OSL), a medical device company specialising in targeted radiotherapy for pancreatic cancer, has announced an $8 million equity raising. The capital raise comprises a $6 million placement and a $2 million non-renounceable entitlement offer, designed to fund the company’s ongoing commercial expansion, clinical trials, and manufacturing capacity enhancements.

The raising is underpinned by strong commercial momentum in Europe, where the OncoSil device is approved for sale in over 34 countries and is gaining traction across multiple hospital centres. The company’s CEO, Nigel Lange, emphasises that the funds will accelerate the rollout of the device, support label expansions, and underpin regulatory submissions in key markets.

Clinical and Commercial Progress

OncoSil’s device delivers brachytherapy using phosphorus-32 microparticles implanted directly into pancreatic tumours, offering a novel approach in a field with limited survival improvements over the past two decades. The company highlights compelling clinical data showing significant survival benefits and increased surgical resection rates when OncoSil is combined with standard chemotherapy regimens.

Recruitment for pivotal clinical trials, PANCOSIL, which explores percutaneous delivery methods, and TRIPP-FFX, which investigates combination with FOLFIRINOX chemotherapy, has been completed. Data readouts are anticipated in the first half of 2026, potentially unlocking broader market access and label expansions.

Commercially, OncoSil is expanding its footprint in Europe, with active implanting centres growing rapidly in Germany, Spain, Italy, Turkey, and other countries. Notably, the German Federal Joint Committee (G-BA) trial is underway, with first patient treatments completed and a tender process progressing to appoint a contract research organisation. This trial is expected to provide level 1 evidence critical for reimbursement and guideline inclusion.

Manufacturing and Financial Outlook

OncoSil has invested $2.1 million in a new manufacturing facility in Sydney, which is now operational and poised to support commercial production. The facility’s capacity aligns with a potential $98 million revenue opportunity at approximately 70% gross margin once scaled. The equity raise will also fund ongoing clinical investments and sales and marketing initiatives to drive adoption.

The offer price for new shares is set at $0.68, representing a 15% discount to the last closing price, and includes one free attaching option for every new share issued, exercisable at $0.90 until June 2027. Bell Potter Securities is acting as sole lead manager and underwriter for the raising.

Navigating Risks and Future Catalysts

While OncoSil’s technology addresses a significant unmet medical need in pancreatic cancer, the company acknowledges inherent risks including regulatory approvals, clinical trial outcomes, manufacturing scale-up, and market acceptance. The upcoming 18 months are catalyst-rich, with trial data releases, regulatory submissions for label expansions, and commercial ramp-up in new and existing markets.

Investors will be watching closely as OncoSil seeks to translate promising clinical evidence into sustainable commercial success in a challenging oncology landscape.